Print E-mail
Volume 37, Number 1, February 2004

Soluble CD26/30 levels before and after treatment with interferon-alpha and ribavirin combination therapy in a pediatric hepatitis C patient


Yu-Ru Liao, Chen Po-Yen, Chieh-Chung Lin, Lin-Shien Fu, Chen-Chia Chiu, Ching-Shiang Chi
Divisions of Immunology, Rheumatology and Allergy, Infectious Diseases, and Gastroenterology, Department of Pediatrics, Taichung Veterans General Hospital, Taichung; and Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan, ROC

Received: July 15, 2003    Revised: August 23, 2003    Accepted: August 29, 2003   

 

Corresponding author:

Dr. Lin-Shien Fu, Department of Pediatrics, Taichung Veterans General Hospital, No.160, Section 3, Chung-Kang Road, Taichung, Taiwan 40705, ROC. E-mail: linshienfu@yahoo.com.tw This e-mail address is being protected from spam bots, you need JavaScript enabled to view it



 

Methods:

Chronic hepatitis C virus (HCV) infection frequently leads to end-stage liver diseases and extrahepatic complications. Combination therapy with interferon-alpha (IFN—α) and ribavirin is now recommended as the first-line therapy for patients with chronic hepatitis C in adults. However, the benefit of such combination therapy in children with hepatitis C is still under investigation. We report here on a 6-year-old boy admitted with chronic active hepatitis C infection and treated with interferon-α and ribavirin. After treatment for 12 months, his serum showed negative HCV RNA, and normal alanine aminotransferase, and there was a sustained response. The patient¡¦s serum soluble CD30 (sCD30) level was higher than that of controls (>100 U/mL vs 46 ± 11 U/mL) before combination therapy but there was no difference in soluble CD26 (sCD26) [103 ng/mL vs 119 ± 28 ng/mL]. The sCD30 decreased and sCD26 increased at 6 months (45 U/mL and 188.3 ng/mL, respectively) using combined therapy as well as at 4 months after discontinuing it (33 U/mL and 167.8 ng/mL, respectively) in our patient. The results indicate that combined treatment with IFN-α and ribavirin may be used as the first-line treatment for children with chronic hepatitis C. The changes of sCD30 and sCD26 may be helpful in estimating of HCV infection activity.

 



 

Key words:

CD30, CD26, hepatitis C, interferon-alpha, ribavirin



 



 

J Microbiol Immunol Infect 2004;37:67-70.